12月2日,先声药业公告,“先必新”舌下片(依达拉奉右莰醇舌下片)于12月1日获得中国国家药品监督管理局(NMPA)批准在中国上市,用于改善急性缺血性脑卒中(AIS)所致的神经症状、日常生活活动能力和功能障碍。2020年,先必新(注射剂型)作为一类创新药已经在国内上市,是全球近十年来卒中领域唯一获批的创新药。作为一种双靶点脑细胞保护剂,先必新含依达拉奉和右莰醇两种活性成分,将抗氧化、抗炎两种作用...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.